SecurAcath Catheter Securement Device Now Recommended in Infusion Therapy Standards of Practice

PLYMOUTH, Minn.–(BUSINESS WIRE)–Interrad Medical announces the SecurAcath device is now recommended in
the 2016 Infusion Therapy Standards of Practice just released by the
Infusion Nurses Society (INS).

The Standards provide the most comprehensive guidance related to the
infusion specialty. The Standards were first published in 1977 and have
been periodically revised since. For the 2016 revision, each standard
underwent an extensive review to ensure each was evidence-based and
clinically sound. Each standard provides criteria for action and
accountability, and the practice criteria are supported by the latest
available research.

Key points within the Standards covering Vascular Access Device (VAD)
Stabilization:

  • Consider use of engineered stabilization device (ESD) as inadequate
    stabilization and securement can cause unintentional dislodgement and
    complications requiring premature VAD removal
  • ESDs promote consistent practice among all clinicians, reduce VAD
    motion that can lead to complications, reduce interruption of needed
    infusion therapy, and may decrease cost of care
  • Avoid use of tape or sutures as they are not effective alternatives to
    an ESD

In the 2016 Standards the SecurAcath has been added in a completely new
category called Subcutaneous Engineered Stabilization Devices (ESDs).
The new Standards state; subcutaneous ESDs have been successful in
stabilizing PICCs and CVADs, patient outcomes and patient and inserter
satisfaction have been favorable.

Another important addition to the 2016 Standards for VAD stabilization
is a caution to be aware of the risk of medical adhesive-related skin
injury (MARSI) associated with the use of adhesive-based ESDs. Skin
injury is a major issue with adhesive securement devices that use of the
SecurAcath eliminates.

“Inclusion in the Standards supports the results we have had with the
SecurAcath. We have had far fewer catheter migrations and dislodgements
and have eliminated skin injury issues compared to the adhesive
stabilization device we used to use,” commented Mark Rowe, RNP, MNSc,
VA-BC.

“We are very pleased that the Standards have recognized the
effectiveness of the SecurAcath. This recommendation is a significant
step in the SecurAcath becoming the new standard of care for catheter
securement,” said Joseph Goldberger, President and CEO of Interrad
Medical.

About the SecurAcath
The SecurAcath is the only ESD that
lasts the life of the line and can dramatically decrease catheter
dislodgement and migration, decrease catheter replacement costs, prevent
therapy interruption, improve vessel health and preservation, reduce
catheter complications and lower total cost of patient care. For more
information visit www.securacath.com

About Interrad Medical, Inc.
Plymouth, Minnesota-based
Interrad Medical, Inc. is a developer, manufacturer and marketer of
medical devices designed for minimally-invasive interventional and
surgical procedures. The Company was founded by practicing
Interventional Radiologist and Interrad Medical Chairman and Chief
Medical Officer, Michael Rosenberg, M.D.

This press release contains forward-looking statements. The Company
wishes to caution the reader of this press release that actual results
may differ from those discussed in the forward-looking statements and
may be adversely affected by, among other things, risks associated with
litigation, clinical trials, the regulatory approval process,
reimbursement policies and commercialization of new technologies.

Contacts

Interrad Medical, Inc.
Jeff Killion, 763-225-6699
jeff@interradmedical.com